April 10, 2021
A spate of news coverage on the results of the Phase I IAVI G001 HIV vaccine clinical trial reflects current public interest in vaccine development amid the ongoing COVID-19 pandemic. ...
Features
April 2, 2021
IAVI recognizes the Government of India for their unwavering support of the development of safe, effective, accessible, preventive HIV vaccines and ...
March 29, 2021
Failure to meet commitments for TB research is not inevitable; the global COVID-19 response may show us the way.
IAVI CEO Mark Feinberg charts future HIV-1 vaccine development efforts in NEJM.
Results illuminate potential way forward for use of broadly neutralizing antibodies to prevent HIV
March 12, 2021
IAVI and partners recently held a webinar on challenges and opportunities for R&D of innovative biomedical treatments for COVID-19.
March 5, 2021
Spotlighting the work of IAVI’s female scientists and global advocates who work to ensure HIV prevention and care reaches adolescent ...
February 12, 2021
Watch our explainer videos describing why we need an HIV vaccine, the vaccine development process, and the concept of vaccine-induced seropositivity.
February 9, 2021
Focus on access, innovation, communities, and partnerships, say leading voices.
February 8, 2021
On January 19, IAVI co-convened a webinar with Wellcome and Unitaid on how COVID-19 may pave the way for global access to ...
February 3, 2021
Exploring potential bottlenecks and providing recommendations to accelerate access to future HIV prevention products.
Show More
Media Contacts
North America
Rose Catlos
+1 212 847 1049
RCatlos@iavi.org
